183 related articles for article (PubMed ID: 33003611)
1. The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease.
Limgala RP; Fikry J; Veligatla V; Goker-Alpan O
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003611
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
[TBL] [Abstract][Full Text] [Related]
3. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
4. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
[TBL] [Abstract][Full Text] [Related]
5. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
Linthorst GE; Aerts JM
J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
[No Abstract] [Full Text] [Related]
6. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
7. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.
van der Veen SJ; Vlietstra WJ; van Dussen L; van Kuilenburg ABP; Dijkgraaf MGW; Lenders M; Brand E; Wanner C; Hughes D; Elliott PM; Hollak CEM; Langeveld M
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806627
[TBL] [Abstract][Full Text] [Related]
8. A Fabry Disease Patient Who Developed Hypersensitivity Reaction against Agalsidase Beta following COVID-19 Infection.
Sonmez O; Ozcan SG; Trabulus S; Seyahi N
Nephron; 2023; 147(3-4):199-202. PubMed ID: 36174537
[TBL] [Abstract][Full Text] [Related]
9. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB
J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
13. Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson-Fabry disease.
Stamerra CA; De Feo M; Castelli V; d'Angelo M; Cimini A; Grassi D; Ferri C
Eur J Hum Genet; 2021 Feb; 29(2):218-224. PubMed ID: 32948848
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
16. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
[TBL] [Abstract][Full Text] [Related]
17. A revised home treatment algorithm for Fabry disease: influence of antibody formation.
Smid BE; Hoogendijk SL; Wijburg FA; Hollak CE; Linthorst GE
Mol Genet Metab; 2013 Feb; 108(2):132-7. PubMed ID: 23332169
[TBL] [Abstract][Full Text] [Related]
18. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.
Bodensteiner D; Scott CR; Sims KB; Shepherd GM; Cintron RD; Germain DP
Genet Med; 2008 May; 10(5):353-8. PubMed ID: 18496035
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M; Brand E
Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
